NCT05920941View on ClinicalTrials.gov

Mass Balance Study of [14C]JAB-21822

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 8, 2023

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions
Mass Balance Study in Healthy Subjects
Interventions
DRUG

[14C]JAB-21822

Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY